Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems, Inc. (NASDAQ: KRMD) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on large-volume subcutaneous infusion solutions. News about KORU Medical frequently centers on its Freedom Syringe Infusion System, financial performance, regulatory milestones, and collaborations with biopharmaceutical partners.
Investors following KRMD news can expect regular updates on quarterly and annual financial results, including net revenue trends, core business performance, and contributions from Pharma Services and Clinical Trials. The company often provides revenue guidance and discusses metrics such as gross margin and cash position in its earnings-related press releases, which are also referenced in Form 8-K filings.
KORU Medical’s news flow also highlights regulatory and clinical developments. This includes FDA 510(k) submissions for the Freedom System to be used with specific biologic drugs, such as rare disease therapies and oncology biologics like PHESGO for HER2+ breast cancer. The company reports clinical and real-world evidence, including multicenter evaluations comparing the FreedomEdge Infusion System with manual push techniques in oncology and immunology settings, focusing on nurse satisfaction, patient comfort, and workflow efficiency.
Another key news category involves strategic collaborations and development agreements with pharmaceutical and medical technology partners. Examples include agreements to develop next-generation subcutaneous immunoglobulin infusion systems and to integrate the FreedomEdge pump into wearable infusion platforms for targeted antibiotic delivery in periprosthetic joint infection.
In addition, KORU Medical issues announcements about leadership appointments, equity awards, and participation in investor conferences, providing insight into its management priorities and engagement with the investment community. For ongoing coverage of KRMD, this news page aggregates company press releases and related updates so readers can monitor financial disclosures, regulatory progress, and partnership activity over time.
KORU Medical Systems authorized a stock repurchase program allowing for the purchase of up to $10 million of its common stock until December 31, 2021. CEO Don Pettigrew emphasized that this decision reflects confidence in the company's long-term outlook and shareholder value maximization. The repurchase will be financed with cash on hand and executed through open market or private transactions, depending on market conditions. The board views this initiative as a commitment to enhancing shareholder value and believes in the company's growth potential.
KORU Medical Systems (NASDAQ: KRMD) reported Q3 2020 financial results, revealing net sales of $6.1 million, a decrease from $6.6 million in Q3 2019. Despite this, net sales for the first nine months increased 19% year-over-year. Gross profit also declined to $3.9 million, reflecting a 64.8% margin. Net income fell to $0.2 million, or $0.01 per share, down from $0.7 million in the previous year. The company retains a solid cash position of $32.4 million. KORU is optimistic about upcoming product launches and clinical trials that could expand its market presence.
KORU Medical Systems (NASDAQ: KRMD) will release its financial results for Q3 2020 on November 3, 2020, after market close. A conference call is scheduled for November 4, 2020, at 9:00 am ET to discuss the results and business activities. Interested participants can join the call via telephone or online. KORU Medical specializes in specialty infusion solutions that enhance patient quality of life, with products like the FREEDOM Syringe Infusion System.